%0 Journal Article
%A Moraitis, Alexandros
%A Prochnow, Andre
%A Poeppel, Thorsten Dirk
%A Schmitz, Jochen
%A Laschinsky, Christina
%A Herrmann, Ken
%A Bockisch, Andreas
%A Fragoso Costa, Pedro
%A Kersting, David
%A Jentzen, Walter
%T Tumor Dose-Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET.
%J Journal of nuclear medicine
%V 66
%N 4
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2025-00570
%P 641–647
%D 2025
%Z 66(4), pp. 641–647
%X [131I]Metaiodobenzylguanidine (MIBG) therapy in patients with neural crest tumors has demonstrated sustained control of catecholamine-associated hypertension and corresponding partial response. Details on how neural crest tumors respond to an absorbed dose delivered by [131I]MIBG-targeted therapies is insufficiently known. The primary aim of this retrospective study was to assess the tumor dose-response relationship by means of quantitative analysis of [124I]MIBG PET data. Methods: The tumor dose-response relationship was studied in patients with advanced malignant pheochromocytoma, neuroblastoma, or paraganglioma receiving [131I]MIBG treatment, as well as pretherapeutic and follow-up [124I]MIBG-based dosimetry. [124I]MIBG PET imaging was performed around 4, 24, 48, and 120 h after injection. Lesion uptake was projected to [131I]MIBG for every time point, and respective time-integrated activity coefficients (TIACs) for [131I]MIBG were calculated and used for tumor-absorbed dose estimation. Functional response was denoted for decrease of maximal lesion uptake or TIAC by at least 30
%K PET (Other)
%K [124I]MIBG (Other)
%K [131I]MIBG (Other)
%K dose response (Other)
%K neural crest tumor (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40081949
%R 10.2967/jnumed.124.269377
%U https://inrepo02.dkfz.de/record/299833